GYS1 has emerged as a therapeutic target for several glycogen storage diseases (GSD), including GSD type II (Pompe disease)23, GSD type IV (Andersen disease and adult polyglucosan body disease)24 and Lafora disease25. This evidence concerns the gene GYS1 and glycogen storage disease due to glycogen branching enzyme deficiency.